Ardent HealthvsMerck & Company

ARDT and MRK stock compared: price, dividend, valuation and results, from SEC filings.

ARDT

Ardent Health, Inc.

$14.40

Value $2.1B

-18.87%
ARDT's page

MRK

Merck & Company, Inc.

$137.78

Value $341B

-3.90%
MRK's page

Ardent Health (ARDT) has a market value of $2.1B and Merck & Company (MRK) $341B. Over the last year, with dividends, ARDT moved +73.9% and MRK +52.7%. The P/E is 14.1 for ARDT and 138.9 for MRK. Dividend yield: ARDT none, MRK 2.47%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ARDT$2.1B

    MRK$341B

    MRK is 166 times ARDT

  • Revenue, 12 months

    ARDT$6.5B

    MRK$67.4B

    MRK is 10 times ARDT

  • Net income, 12 months

    ARDT$146M

    MRK$2.5B

    MRK is 17 times ARDT

  • Operating margin

    ARDT–

    MRK–

  • ROIC

    ARDT9.5%

    MRK3.9%

    5.6 points apart

  • P/E

    ARDT14.1

    MRK138.9

    MRK is 9.9 times ARDT

  • Dividend yield

    ARDT0.0%

    MRK2.5%

    2.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ARDT+73.9%

MRK+52.7%

100150200DecFebAprJunAugOct
Returns by period
PeriodARDTWith dividendsMRKWith dividends
1 year since November 17, 2025+73.9%Price +73.9%+52.7%Price +48.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ARDTArdent HealthMRKMerck & Company

Valuation

ARDTMRK
Valuation
Price$14.40$137.78
Market value$2.1B$341B
Enterprise value (EV)$2.4B$385B
P/E14.1138.9
P/E, 5-year median–14.8
P/B1.57.6
EV/EBIT8.280.8
Free cash flow yield–4.3%

Results and growth

ARDTMRK
Results and growth
Revenue, 12 months$6.5B$67.4B
Net income, 12 months$146M$2.5B
Free cash flow, 12 months–$14.7B
Earnings per share, 12 months$1.03$0.98
Revenue growth, year on year6.0%1.3%
Revenue growth a year, past+7.2%over 3 years+9.4%over 5 years
EPS growth a year, past-13.8%over 3 years+21.2%over 5 years

Margins and returns on capital

ARDTMRK
Margins and returns on capital
Gross margin–71.8%
Operating margin––
Net margin2.3%3.6%
ROIC9.5%3.9%
ROE11.1%5.2%

Balance sheet

ARDTMRK
Balance sheet
Cash$766M$9.7B
Total debt$1.1B$53.8B
Net debt / EBITDA0.75.7
Interest cover–2.4×

Dividends and buybacks

ARDTMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.5%
Shareholder yield–4.0%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ARDT or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Ardent Health or Merck & Company?

By market value, Merck & Company ($341B) is about 165.5 times Ardent Health ($2.1B), at today's prices.

How did ARDT and MRK stock do over the last 1 years?

Since November 17, 2025, ARDT's price moved +73.9% and MRK's +48.4%. With dividends: ARDT +73.9% (+73.9% a year), MRK +52.7% (+52.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, ARDT or MRK?

The dividend yield at today's price is none for Ardent Health and 2.47% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

What is the P/E of ARDT and MRK?

At today's price, the P/E is 14.1 for ARDT and 138.9 for MRK. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Ardent Health or Merck & Company?

Over the last twelve months, the net margin was 2.3% for Ardent Health and 3.6% for Merck & Company, and the operating margin – and –. Revenue was $6.5B and $67.4B.

Which is the better investment, Ardent Health or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.